{"status": "OK", "response": {"docs": [{"type_of_material": "Letter", "blog": [], "news_desk": null, "lead_paragraph": null, "headline": {"main": "Drugs: Dangerous Generic Equivalency"}, "abstract": "Pharmaceutical Sciences Acad pres H B Kostenbauder lr maintains that assumption of drug product equivalence without factual evidence represents unwarranted risk to health and welfare of public", "print_page": "46", "word_count": 437, "_id": "4fc479d245c1498b0d9faf50", "snippet": "Pharmaceutical Sciences Acad pres H B Kostenbauder lr maintains that assumption of drug product equivalence without factual evidence represents unwarranted risk to health and welfare of public", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/abstract.html?res=9F05E7D8103DEF34BC4052DFB2668389669EDE", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "DRUGS AND DRUG TRADE"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1}], "original": "H. B. KOSTENBAUDER"}, "document_type": "article", "pub_date": "1972-04-18T00:00:00Z", "section_name": null}], "meta": {"hits": 1, "offset": 0, "time": 53}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}